Notwithstanding promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from pharmacy benefit managers. These insurers are frequently building barriers to reimbursement, including high expense restrictions and prior authorization that hinder consu